Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)

Launched by NHS GREATER GLASGOW AND CLYDE · May 31, 2024

Keywords

ClinConnect Summary

The Bio-SCOTCH clinical trial is studying how certain biological markers in the blood and other tests can help understand the risks of heart diseases linked to genetic factors. These heart diseases, known as cardiomyopathies, can lead to serious problems like heart failure or sudden heart issues. The researchers aim to identify which patients with specific gene variants (like TTN, MYBPC3, LMNA, FLNC, or DSP) are more likely to develop severe conditions and which ones might never experience heart problems. This research could help doctors better monitor patients and tailor their care based on individual risks, rather than relying on expensive tests and procedures.

To participate in this trial, you need to be at least 10 years old and have a known genetic variant linked to cardiomyopathy or be undergoing genetic testing. Participants will give consent and undergo various tests to track their health. It's important to know that those who cannot attend the study location or have serious health issues unrelated to heart disease may not be eligible. By taking part in this study, you could help improve the understanding of genetic heart conditions and contribute to better future care for others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ≥10 years of age
• • Written informed consent / assent
• • Pathogenic or likely pathogenic variant in a cardiomyopathy gene (TTN, LMNA, MYBPC3, DSP, FLNC) or undergoing predictive genetic testing (if negative these people would be invited to enter the control arm)
• Exclusion Criteria:
• • Unable to consent.
• • Geographical / social reasons preventing attending study centre
• • Unable to complete study assessments.
• • Severe non-cardiac disease expected to reduce life expectancy \< 5 years
• • Current participation in a blinded drug interventional trial (or treatment within 4 weeks)